Gene Variant Detail

Gene FGFR2
Variant amp
Impact List none
Protein Effect no effect
Gene Variant Descriptions FGFR2 amp indicates an increased number of copies of the FGFR2 gene. However, the mechanism causing the increase is unspecified.
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 amp FGFR2 over exp stomach cancer sensitive AZD4547 Preclinical - Pdx Actionable In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245). 27401245
FGFR2 amp FGFR2 over exp stomach cancer sensitive BGJ398 Preclinical - Pdx Actionable In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245). 27401245
FGFR2 amp lung non-small cell carcinoma sensitive PRN1371 Preclinical - Pdx Actionable In a preclinical study, PRN1371 treatment resulted in 67.5% tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified non-small cell lung cancer (PMID: 28978721). 28978721
FGFR2 amp stomach cancer no benefit Brivanib Preclinical Actionable In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp colon cancer sensitive Nintedanib Preclinical Actionable In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp myxoid liposarcoma sensitive Dovitinib + Trabectedin Preclinical Actionable In a preclinical study, Dovitinib (TKI258) and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp breast cancer sensitive Debio 1347 Preclinical Actionable In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980). 25169980
FGFR2 amp breast cancer sensitive Debio 1347 Case Reports/Case Series Actionable In a Phase I trial, Debio 1347 treatment resulted in a stable disease with 19.4% reduction of tumor size and 41% decrease of DUSP6 score in a patient with lung squamous cell carcinoma harboring FGFR2 amplification (PMID: 30745300; NCT01948297). 30745300
FGFR2 amp colorectal cancer sensitive Erdafitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Balversa (erdafitinib) inhibited tumor growth in an FGFR2-amplified colorectal cancer cell line xenograft model (PMID: 28341788). 28341788
FGFR2 amp colorectal adenocarcinoma predicted - sensitive RO5126766 Preclinical - Cell culture Actionable In a preclinical study, RO5126766 inhibited proliferation of FGFR2 amplified colorectal adenocarcinoma cells in culture (PMID: 26438159). 26438159
FGFR2 amp colon cancer sensitive AZD4547 Preclinical - Cell culture Actionable In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940). 27550940
FGFR2 amp stomach cancer predicted - sensitive PRN1109 Preclinical - Cell line xenograft Actionable In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157). detail...
FGFR2 amp stomach cancer sensitive BGJ398 Preclinical Actionable In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp uterine cancer predicted - sensitive Debio 1347 Case Reports/Case Series Actionable In a Phase I trial, Debio 1347 treatment resulted in a stable disease with 3.9% change of tumor size and 60% decrease of DUSP6 score in a patient with uterine cancer harboring FGFR2 amplification (PMID: 30745300; NCT01948297). 30745300
FGFR2 amp estrogen-receptor negative breast cancer no benefit Brivanib Preclinical Actionable In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-negative breast cancer cells with FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp stomach cancer sensitive AZD4547 Preclinical Actionable In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148). 22869148
FGFR2 amp stomach cancer sensitive AZD4547 Phase II Actionable In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038). 27179038
FGFR2 amp ovarian cancer sensitive BAY1187982 Preclinical - Pdx Actionable In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601). 27543601
FGFR2 amp stomach cancer sensitive Dovitinib Preclinical Actionable In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp breast cancer sensitive Derazantinib Preclinical - Cell culture Actionable In a preclinical study, Derazantinib (ARQ 087) inhibited growth of breast cancer cells harboring FGFR2 amplification in culture (PMID: 27627808). 27627808
FGFR2 amp myxoid liposarcoma sensitive BGJ398 Preclinical Actionable In a preclinical study, BGJ398 increased apoptosis, and inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp colon cancer sensitive Dovitinib Preclinical Actionable In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp stomach cancer sensitive Erdafitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Balversa (erdafitinib) inhibited proliferation of a gastric cancer cell line with FGFR2 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788). 28341788
FGFR2 amp stomach cancer resistant Selumetinib Preclinical Actionable In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509). 19755509
FGFR2 amp stomach carcinoma no benefit RO5126766 Preclinical - Cell culture Actionable In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159). 26438159
FGFR2 amp breast cancer sensitive Dovitinib Preclinical - Pdx & cell culture Actionable In a preclinical study, Dovitinib (TKI258) inhibited cell growth of an FGFR2 amplified breast cancer cell line in culture and prevented tumor growth and induced tumor regression in FGFR2 amplified breast cancer patient derived xenograft (PDX) models (PMID: 23658459). 23658459
FGFR2 amp stomach cancer sensitive Cediranib Preclinical Actionable In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp Her2-receptor positive breast cancer sensitive Dovitinib Phase I Actionable In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459). 23658459
FGFR2 amp stomach cancer sensitive PD173074 Preclinical - Cell culture Actionable In a preclinical study, FGFR2-amplified gastric cancer cell lines demonstrated sensitivity to PD173074 in culture, with cell lines with high-level FGFR2 amplification displaying higher sensitivity compared to cell lines with low-level amplification (PMID: 27179038). 27179038
FGFR2 amp stomach cancer sensitive PD173074 Preclinical - Cell culture Actionable In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp gastric signet ring cell adenocarcinoma sensitive M-COPA Preclinical - Cell culture Actionable In a preclinical study, treatment with M-COPA resulted in decreased Fgfr2 cell surface expression and phosphorylation and reduced growth of an FGFR2-amplified signet cell gastric cancer cell line in culture (PMID: 27197184). 27197184
FGFR2 amp breast cancer sensitive AZD4547 Preclinical - Cell culture Actionable In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified breast cancer cells in culture (PMID: 27550940). 27550940
FGFR2 amp colon cancer no benefit Brivanib Preclinical Actionable In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp myxoid liposarcoma sensitive PD173074 Preclinical Actionable In a preclinical study, PD173074 increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp breast cancer sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-negative breast cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp stomach carcinoma no benefit RO4987655 Preclinical - Cell culture Actionable In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159). 26438159
FGFR2 amp colon cancer sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp colon cancer sensitive Cediranib Preclinical Actionable In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366). 22238366
FGFR2 amp stomach cancer predicted - sensitive TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). detail...
FGFR2 amp stomach cancer sensitive FIIN-1 Preclinical Actionable In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520). 20338520
FGFR2 amp colorectal adenocarcinoma decreased response RO4987655 Preclinical - Cell culture Actionable In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells demonstrated decreased response to RO4987655 in culture (PMID: 26438159). 26438159
FGFR2 amp stomach cancer sensitive Derazantinib Preclinical - Cell culture Actionable In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 27627808). 27627808
FGFR2 amp stomach cancer sensitive Debio 1347 Preclinical - Cell line xenograft Actionable In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980). 25169980
FGFR2 amp stomach cancer sensitive Ponatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366). 22238366
FGFR2 amp colorectal cancer sensitive Debio 1347 Preclinical Actionable In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980). 25169980
FGFR2 amp breast cancer sensitive BGJ398 Phase I Actionable In a Phase I trial, a breast cancer patient harboring an FGFR2 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574). 27870574
FGFR2 amp gastric adenocarcinoma no benefit AZD4547 Phase II Actionable In a Phase II trial (SHINE), AZD4547 treatment did not improve progression-free survival compared to Taxol (paclitaxel) (1.8 vs 3.5 months, p=0.9581) in advanced gastric adenocarcinoma patients with FGFR2 amplification (PMID: 29177434; NCT01457846). 29177434
FGFR2 amp myxoid liposarcoma sensitive BGJ398 + Trabectedin Preclinical Actionable In a preclinical study, BGJ398 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp stomach carcinoma sensitive Debio 1347 Preclinical - Cell line xenograft Actionable In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159). 26438159
FGFR2 amp Advanced Solid Tumor predicted - sensitive Debio 1347 Phase I Actionable In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297). 30745300
FGFR2 amp stomach cancer sensitive E7090 Preclinical - Cell line xenograft Actionable In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969). 27535969
FGFR2 amp colorectal adenocarcinoma no benefit Selumetinib Preclinical - Cell culture Actionable In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159). 26438159
FGFR2 amp myxoid liposarcoma sensitive Dovitinib Preclinical Actionable In a preclinical study, Dovitinib (TKI258) increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp stomach carcinoma sensitive PRN1371 Preclinical - Cell line xenograft Actionable In a preclinical study, PRN1371 inhibited proliferation of FGFR2 amplified gastric carcinoma cells in culture and tumor growth in cell line xenograft models (PMID: 28978721). 28978721
FGFR2 amp endometrial cancer sensitive AZD4547 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified endometrial cancer cells in cell line xenograft models (PMID: 27550940). 27550940
FGFR2 amp myxoid liposarcoma sensitive PD173074 + Trabectedin Preclinical Actionable In a preclinical study, PD173034 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639). 26036639
FGFR2 amp colon cancer sensitive BGJ398 Preclinical - Cell culture Actionable In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245). 27401245
FGFR2 amp Advanced Solid Tumor predicted - sensitive AZD4547 Phase II Actionable In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060). detail...
FGFR2 amp stomach cancer sensitive ODM-203 Preclinical - Cell line xenograft Actionable In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a gastric cancer cell line with amplification of FGFR2, and inhibited tumor growth in xenograft models (PMID: 30301864). 30301864
FGFR2 amp FGFR2-COL14A1 colon cancer sensitive Derazantinib Preclinical - Cell line xenograft Actionable In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of colon cancer cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture and in cell line xenograft models (PMID: 27627808). 27627808
FGFR2 amp FGFR2-COL14A1 colorectal adenocarcinoma sensitive PRN1371 Preclinical - Cell culture Actionable In a preclinical study, PRN1371 inhibited proliferation of colorectal adenocarcinoma cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture (PMID: 28978721). 28978721
FGFR2 amp FGFR2 fusion breast cancer sensitive PRN1371 Preclinical - Pdx Actionable In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified breast cancer harboring FGFR2-GAB2 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249). detail...
FGFR2 amp FGFR2 fusion stomach cancer sensitive Derazantinib Preclinical - Cell line xenograft Actionable In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification and PDHX-FGFR2 fusion in culture, resulted in tumor regression in cell line xenograft models (PMID: 27627808). 27627808
FGFR1 amp FGFR2 amp breast cancer sensitive E7090 Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). 27535969
FGFR2 amp FGFR2 mut cervical adenocarcinoma predicted - sensitive Debio 1347 Case Reports/Case Series Actionable In a Phase I trial, Debio 1347 treatment resulted in a partial response with 50% reduction of tumor size and 56% decrease of DUSP6 score in a patient with cervical adenocarcinoma harboring FGFR2 amplification and FGFR2 mutation (PMID: 30745300; NCT01948297). 30745300
ERBB2 amp FGFR2 amp esophagus adenocarcinoma sensitive AZD4547 + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477). 27595477
FGFR2 amp FGFR2-GAB2 breast cancer sensitive PRN1371 Preclinical - Pdx Actionable In a preclinical study, PRN1371 treatment resulted in 60.6% tumor growth inhibition in patient-derived xenograft models of breast cancer harboring FGFR2 amplification and FGFR2-GAB2 fusion (PMID: 28978721). 28978721
FGFR2 amp FGFR2 rearrange cholangiocarcinoma predicted - sensitive TAS-120 Phase I Actionable In a Phase I trial, TAS-120 treatment resulted in partial response in a patient with cholangiocarcinoma harboring FGFR2 rearrangement and FGFR2 amplification (Annals of Oncology, Volume 29, Issue suppl_5). detail...
EGFR over exp FGFR2 amp head and neck squamous cell carcinoma sensitive AZD4547 + Gefitinib Preclinical - Cell culture Actionable In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917). 26936917
EGFR over exp FGFR2 amp head and neck squamous cell carcinoma resistant AZD4547 Preclinical - Cell culture Actionable In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). 26936917